
    
      OBJECTIVES: I. Determine the response rate, failure-free survival, and overall survival of
      interleukin-2 and interferon alpha administered subcutaneously on an outpatient basis for 8
      weeks to patients with metastatic cancer. II. Determine the toxicities associated with this
      therapy.

      OUTLINE: Biological Response Modifier Therapy. Interleukin-2 (Cetus), IL-2, NSC-373364;
      Interferon alpha (Schering), IFN-A, NSC-377523.

      PROJECTED ACCRUAL: Up to 30 patients with various malignancies will be entered.
    
  